Clinical Trial Detail

NCT ID NCT03557359
Title Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Columbia University
Indications

malignant glioma

Therapies

Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST